Smith & Nephew (SNN) completed its acquisition of Osiris Therapeutics, provider of regenerative medicine products including skin, bone graft and articular cartilage substitutes. Osiris is now an indirect wholly-owned SNN subsidiary.
The acquisition is expected to accelerate growth from SNN’s Advanced Wound Management segment. As previously noted, Osiris also brings BIO4® viable bone matrix, an alternative to autograft, and Cartiform® cryopreserved viable osteochondral allograft for articular cartilage repair.
Smith & Nephew (SNN) completed its acquisition of Osiris Therapeutics, provider of regenerative medicine products including skin, bone graft and articular cartilage substitutes. Osiris is now an indirect wholly-owned SNN subsidiary.
The acquisition is expected to accelerate growth from SNN's Advanced Wound Management segment. As previously...
Smith & Nephew (SNN) completed its acquisition of Osiris Therapeutics, provider of regenerative medicine products including skin, bone graft and articular cartilage substitutes. Osiris is now an indirect wholly-owned SNN subsidiary.
The acquisition is expected to accelerate growth from SNN’s Advanced Wound Management segment. As previously noted, Osiris also brings BIO4® viable bone matrix, an alternative to autograft, and Cartiform® cryopreserved viable osteochondral allograft for articular cartilage repair.
Copy to clipboard 
